Nucor earnings beat by $0.08, revenue fell short of estimates
Acadia Healthcare (NASDAQ:ACHC)’s stock has reached a new 52-week low, touching $20.36, representing a stark decline from its 52-week high of $82.41. According to InvestingPro analysis, the company currently trades at just 0.63 times book value, suggesting potential undervaluation. This marks a significant downturn for the company, as its shares have experienced a sharp decline over the past year. The stock’s 1-year change stands at a substantial decrease of 70%, reflecting a challenging period for the healthcare provider. Despite the decline, InvestingPro data shows the company remains profitable with $2.04 earnings per share, though 10 analysts have recently revised their earnings expectations downward. This drop to a 52-week low underscores the ongoing pressures and market conditions affecting Acadia Healthcare, which currently maintains a market capitalization of $1.89 billion. Discover more insights with InvestingPro’s comprehensive research report, available along with additional ProTips.
In other recent news, Acadia Healthcare’s first-quarter results for 2025 aligned with expectations, reporting revenue of $770.5 million and adjusted EBITDA of $134.2 million, slightly surpassing projections. Despite some unusual costs from government investigations, the company maintained its full-year guidance, projecting revenues between $3.3 billion and $3.4 billion, with adjusted EBITDA ranging from $675 million to $725 million. Raymond (NSE:RYMD) James reaffirmed a strong buy rating with a $40.00 price target, citing the company’s performance and future prospects. Meanwhile, UBS reiterated a buy rating with a $45.00 target, noting potential impacts from a delay in Tennessee’s directed payment program approval, which could affect second-quarter results. RBC Capital maintained an Outperform rating with a $43.00 target, expressing confidence in Acadia’s long-term growth strategy, particularly the development of new facilities. Cantor Fitzgerald kept a neutral rating and a $40.00 price target, highlighting the stability of Acadia’s inpatient psychiatric segment despite previous media scrutiny. The Senate’s proposal to adjust provider tax regulations could impact healthcare operators, including Acadia, but Cantor noted that the changes might be less severe than anticipated. These developments reflect ongoing strategic and financial adjustments as Acadia Healthcare navigates regulatory and operational challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.